Enemy Intel Inflicting enough damage will pressure him. When his HP is reduced, he will fuse with scrap metal to perform powerful attacks. During this time, he will be difficult to pressure. However, ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion ...

Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

Dyne Therapeutics (DYN) is stepping into a pivotal week, with investors laser focused on tomorrow’s topline readout from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for DYNE-251 ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...

It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind. That research note was published on Sunday ...

The Tennessee Titans currently hold nine picks in the 2026 NFL Draft following the trade deadline. Three in-season trades involving Jarvis Brownlee Jr., Roger McCreary and Dre'Mont Jones have altered ...